<SEC-DOCUMENT>0001269026-15-000009.txt : 20150723
<SEC-HEADER>0001269026-15-000009.hdr.sgml : 20150723
<ACCEPTANCE-DATETIME>20150723162348
ACCESSION NUMBER:		0001269026-15-000009
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20150723
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150723
DATE AS OF CHANGE:		20150723

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMEDICA Corp
		CENTRAL INDEX KEY:			0001269026
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33624
		FILM NUMBER:		151002546

	BUSINESS ADDRESS:	
		STREET 1:		1885 WEST 2100 STREET
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84119
		BUSINESS PHONE:		801-839-3516

	MAIL ADDRESS:	
		STREET 1:		1885 WEST 2100 STREET
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84119

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMEDICA CORP
		DATE OF NAME CHANGE:	20031104
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a20150723_8-kxorthodevelop.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>2015.07.23_8-K - Ortho Development OEM Announcement</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s663be19963c54a958ffd50a0fb41f731"></a><div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;"><hr></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM&#160;8-K</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Securities Exchange Act of 1934</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of report (Date of earliest event reported): July 23, 2015</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">Amedica Corporation</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="32%"></td><td width="2%"></td><td width="32%"></td><td width="2%"></td><td width="32%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:Times New Roman;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">001-33624</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:Times New Roman;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">84-1375299</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:Times New Roman;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">File Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:Times New Roman;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="49%"></td><td width="2%"></td><td width="49%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1885 West 2100 South</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Salt Lake City, UT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:Times New Roman;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">84119</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:Times New Roman;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant&#8217;s telephone number, including area code: </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(801) 839-3500</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former Name or Former Address, if Changed Since Last Report)</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">see</font><font style="font-family:inherit;font-size:10pt;">&#32;General Instruction A.2. below):</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160; Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160; Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160; Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160; Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;"><hr></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><br><div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s663be19963c54a958ffd50a0fb41f731"></a><div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01 Other Events.  </font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 23, 2015, the Registrant issued a press release announcing that it has signed an original equipment manufacturer (OEM) letter of intent supply agreement with a leading orthopedic device design and manufacturing company.  A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01 Financial Statements and Exhibits.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibits</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press Release dated</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">July 23, 2015.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><br><div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s663be19963c54a958ffd50a0fb41f731"></a><div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURE</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="50%"></td><td width="50%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:Times New Roman;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">AMEDICA CORPORATION</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Date: July 23, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ Ty Lombardi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:Times New Roman;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Ty Lombardi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:Times New Roman;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Vice President, Finance </font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><br><div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s663be19963c54a958ffd50a0fb41f731"></a><div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:right;padding-left:24px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit 99.1</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:24px;text-indent:0px;"><img src="amedicaa04.gif" style="height:88px;width:165px;"></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Amedica Corporation Signs Additional OEM Letter of Intent Supply Agreement </font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SALT LAKE CITY,&#160;July 23, 2015 -&#160;Amedica Corporation&#160;(Nasdaq:AMDA), a biomaterial company that has developed silicon nitride ceramics as a material platform to manufacture and commercialize orthopedic implants, is pleased to announce that it has signed an original equipment manufacturer (OEM) letter of intent supply agreement with a leading orthopedic device design and manufacturing company. </font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Under the proposed agreement, Amedica will assist this company with their proprietary design, development, manufacture and supply of silicon nitride spinal implants. The two companies will begin negotiating the definitive agreement once it is satisfied that all necessary and appropriate regulatory approvals can be obtained without significant expense. The agreement underscores Amedica&#8217;s continued focus to provide superior and innovative solutions to the market.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;We are very pleased to announce an additional partner to this growing lineup of OEM partnerships,&#8221; said Dr. Sonny Bal, chairman and CEO of&#160;Amedica Corporation. &#8220;We remain committed to offering our customers a biomaterial that contains distinct benefits to improve the efficacy of spinal fusion procedures, resulting in enhanced patient care. I am convinced that this, as well as the three additional private label and OEM agreements we&#8217;re anticipating to complete this year, will lead to faster and more widespread market penetration of silicon nitride, positioning it as the biomaterial of choice for medical applications.&#8221;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Silicon nitride is a unique biomaterial that can be shaped and engineered into complex designs and surfaces to address a variety of medical needs. Unlike other leading biomaterials in the market today, silicon nitride contains anti-bacterial properties and also supports rapid bone on-growth and in-growth. This combination of optimal material properties is unique to Amedica&#8217;s silicon nitride material platform. </font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About&#160;Amedica Corporation</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Amedica is focused on the development and application of medical-grade silicon nitride ceramics. Amedica markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Company manufactures its products in its ISO 13485 certified manufacturing facility and, through its partnership with Kyocera, the world's largest ceramic manufacturer. Amedica's spine products are FDA-cleared, CE-marked, and are currently marketed in the U.S. and select markets in Europe and South America through its distributor network and its growing OEM partnerships.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">For more information</font><font style="font-family:inherit;font-size:11pt;">&#32;on Amedica or its silicon nitride material platform, please visit&#160;www.amedica.com.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Forward-Looking Statements</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the Company&#8217;s expectation that it will enter into three additional private label and OEM agreements this year and that this will lead to faster and more widespread market penetration of silicon nitride, the intent, belief or current expectations of Amedica and members of its management team with respect to Amedica's future business operations as well as the assumptions upon which such statements are based. Such forward-looking statements are subject to risks and uncertainties such as whether the Company will be able to agree on the terms of a definitive OEM supply agreement, whether the potential new OEM partner will be able to obtain all necessary and appropriate regulatory approvals from the applicable regulatory authorities without significant expense, the timing and success of new product introductions, FDA review and clearance, physician acceptance, endorsement, and use of Amedica's products, regulatory matters, competitor activities, changes </font></div><br><div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s663be19963c54a958ffd50a0fb41f731"></a><div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">in and adoption of reimbursement rates, potential product recalls, effects of global economic conditions and changes in foreign currency exchange rates. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found in Amedica's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 24, 2015, and in Amedica's other filings with the SEC. Amedica disclaims any obligation to update any forward-looking statements.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Contact:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mike Houston</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">VP, Commercialization &amp; Communications</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">801-839-3534</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">mhouston@amedica.com</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><br><div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>amedicaa04.gif
<TEXT>
begin 644 amedicaa04.gif
M1TE&.#EAGP'@`(<```@*"PX0$A$3%!47&!88&1D;'1P?(!X@(2(D)"4G*"8H
M*2HK+"TN,"XP,34W.#T_0#Y`0$)$1$9(2$M,34Y04%=865Y@8&-D965G:&9H
M:6ML;6UO<&]P<7-T=71U>79X>WEV>7I\?'MXA7>!CGZ`@WF!BGV"D'Z+G7R4
MKX1W;81^?(5^@HA]@89_D)1[@IM]B(^"=HR">Y*#=JN3>_NO,ONP,_RS._RU
M0_RW2/VY0/RX2_R\4_R^7/W`5_W#8?S#:_W);OS&<?W(=OW*?(>'B(:*E(Z0
MDI>/AY*(B9J%@IF/A92+DY:/F)V/EY:1CIV1AIR2BY*2DY.4FI:8FYJ3DIJ4
MFYJ;FXN5IXF;LY:;IY.?M(VAN92@K)RAHYNBJI6CM)*ENIJELIJHM9JIO*.*
MBJN5BJ*4D:.;E*2<FZV;DJN<F["8@J*<HZJDG;BBCK*BE;:FF[:HG;ZFE;JH
MG*:FIJ.FM*.KLZ6MO*ZOL*VRL*VSN[.JH[:MJKFLI[VRIKVRJ[.SM+2WN+>X
MN+RZM;N[NYJMPYNSR)JWT*BUQ*2\T;6^Q[*]RKJ\P:_!R*?!VK+`S;_`P+K$
MSKK)S[?)U[[1WZO&X+'*XKK-X;?1X+G1X[C2Z;_9YL&LF<FOF\:MH<BXJ<2V
ML,6\LLR]L].]JLFZP<7`NL["M\S$NLO+O-/#K]?(N/W,A/W.B?W1A/W1B_W4
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M^O?X\?7Y^_GV\?WZ\_[^_B'_"TY%5%-#05!%,BXP`P$!```A^00``````"P`
M````GP'@```(JP#_"1Q(L*#!@P@3*ES(L*'#AQ`C2IQ(L:+%BQ@S:MS(L:/'
MCR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-FSASZMS)LZ?/GT"#"AU*M*C1
MHTB3*EW*M*G3IU"C2IU*M:K5JUBS:MW*M:O7KV##BAU+MJS9LVC3JEW+MJW;
MMW#CRIU+MZ[=NWCSZMW+MZ_?OX`#"QY,N+#APX@3*U[,N+'CQY`C2YY,N;+E
MR[B8,VO>S+FSY\^@0XL>3;JTZ=.H4ZM>S;JUZ]>P8\N>3;NV[=NX<^O>S;NW
M[]]Y\=D;3IRX/^#()?H3ARN7\^?.R1U/3ITAN5>PFD-W+LY>]>\(\>%JQ:K6
M]N?2P:L?>'W5JNSG<W5?KQY?+?>K6-&*+W\Z?>KBN(+?*J]HM]U\_R7G3RP#
MNK=??.+XEZ!O`3:8GX'0B7/.A+_9(XN%[L'"7X0<\N8/+@*"R(HM_&U8HF[G
M?`ABB"/>__,B;B>F.&-Y$+IX8VWMS8C?*S7^2-L]M^@HI'X0FB.AD:Z)\XJ0
M#18(H7=0OF8/+50VR&1\3F;9VG)*XO=#$""^8MYY"(JIVI8@!H'##D.`*&)\
MZ;F)FC^YE.D>#S78\`.(KJQY()9ZFA9CG#?00(,.=5IX)YM/)@I:CB#NX&B@
M/JAH:(8^6AK:.5-:&(0--:1*PPV15CDB/J*&YL]](.I`0ZJX\C#CI\]I&"MH
MY/BYR@\U;%HL#3:T.J"5;-KX*V?^<&GA$(WBBJL-L`C[X('F/,M9A1;Z4.RQ
MJ=K0RCW2>HEAK\YZ>]D],C8H1+7&UM"#./\$:R=_Y+A[&9_"`O5ZJ[4VO'*<
M/[>HR"*;B/HKV:*F5CONK3[T*U`YI38XZ79Y.@P9P-/N,"ZY-M#B'Z9>\LI=
MPQXW1@XL(/YP@[6X`A'J/^?`;"&S'%?:,F+B^3F$R#37H,,M3X+LY;89LOPS
M8D$V^`.J$P<ZA-/_P+GSNMSY_/1@]]`JKPY5I[I#+@F!.^"7!][\-6%2@BBN
MJ@.;ZW76Z2Z[\(&POEV8U@T&0:^J]N*K4-R2]N@W862""&C1!<,JX<GVU.(*
M*YAG_LK>&?:].&`>QFG#K:0[>K8YJ*>N.NKDY%++Z["_SK5\Y]S]^5U]9DHZ
MKK>Z(I\XW(DC/'_$-_][NU^DBCXP[V<7[[SSXG1[/%^WM%+K[JH6_/SVQ(O3
M[O1WE2/LW#33\`/WZ$-H._AMS0HBM<N3?H,LZ=??*];LOZ7V@.1/3(,0L[/?
M\TB4O[GD+G`2XYT.LH.+!CKP@1",H`0GV!RW%;`MR6N0P!RU/!V<*0@@#*$(
M1TC"$IHP"$*0Q07E<B*IS:QH,(RA#&<(0QNH<(5Q.8>.AE:^D<$0>SZTUO((
M%\21[<"".%Q+NJ9&PQ@:JW0<!"*YA&BM5B11+OH:VA!Y1\4FRG"(6TQ5#@QW
MQ;=$:Q4^H)H7J3BP>H71B=8:POK*:!9QK()L:\RC'G$U1CK&!1^R\($@!TD\
MR$(:\I"(3&0A6^$Y/[K%'N>(I"0G2<E*6O*2F*0D_AS)R4YZ\I.@#*4H1TG*
M4IKRE*A,I2I7R<I6NO*5_[",I2Q?DH]\S%(QT-"%+J!ARUL6!AUTL((5Z(`.
M7Q8F&5:(PC"+"9IV,#,D^6A'0]#1RXR@0Y?8S&8R,I*/;.HR&=3\2#MV"9)V
M)`.;O#1).@\"C6$"@IC-C`(1I!F29!0!&@O)1PATL1$Z.*`!``UH`QQP@6I6
M1!?_#*@#'`"!"A"!GQQAQ`3FV1%"A&`""QTH!"XPA6>"!!T5``1"NDD'0.C"
MH)S1Q0(<(-*0$,(!5D!I0?"P@)9FQ`H"J$`4=LK3*-!!IA+110$<L%,B$*$#
M%7#`4$.`3XT`8@$=H&=&H-&!!2`@`AL@@CR3>H`(_#0D1`A`!:1:D&BV`ZB9
M:?]'!P````V0M2-T",`$('J0=E```$38B!4*D%>0Z,(`%R!(+:&1!0<0X`)-
MQ<A3HZH1752``!+`0S@%DH]D$"$!"H@"6B\"#04```%T8`TA###0!7S5(_D@
M`@`$0`2@YB,*!0!`8#6RU[Y^Y*^S-0@T*E``#[R5(HO][422,0$",!8ACJ5H
M1_+1`0%,``$32.QIVE$!`TR!#@JH@'0WT@X-%&"EA#B(+B+0@`$\0*]\#0EN
M$S)>EF8DN!AI1P@*@`&/'J26'R'$2I.A@0,88;.@H4,!*H`.:%P`M`"F"#0F
M,%$'<,"^[2!!9B.0`.%.9*\=@(:&-PP-^U)DO2,E`E__$]P0^%YDO`T([TK4
M<0$"6.$?*ITK:M`1`=`*A`X-H,!V,X+0"R0C`PT(+4$$X0#M9J``=+V(%0)0
MY`HX^<FVM0B($0((!6C`PQ(QL46P2V"6T&$!$2BF?!'0VM-$80`7H"<Z-&"`
MF%:T`2'(!R"*_$QT<,`!/R4"`82,$9PZ0`.`#K0&I,!CP"KDI1?`<D2T7!$K
M&.`#%AX)-BJ`X']TTP$12+)HDA$!V1KATT2HP``BL$V.8#<*_QCSB_^A#W]>
M^1]T8"UM"Q`"=-CZUNB(-$2F?!!"-"#1BH6JKAUBA0/X5B7YL`("$!""3QN!
M"`\0``F&G9G4#N"[`EU``62]_Y'4FE8@[<7G;AV@XK]F@,0-J:UZ#9T0.AP@
M!-1F"*.!NP#MJB09%1#``03:@`0(@-RD0:AI"4'P@G^9`3NN2#XNX`"ZGKFU
M5E"`"'H)C09,(-X,4;=?V7V0-=LXV,>U"'%KFI+7`A80!2]X!PP0\L_D8P,C
M/@@1!-`![D8@`HG-QP048(4(R%@@[8@`PF^:WHWGMB#M$+$%$IYE86,D'T8P
M@+T5<M:-Z`("#H#$0?!]`!6#)@\.D`#3H1$!)&LD&=DUZ&@+@(!5#^3`FJ:(
MQF_+<4M'4Q<=*$`$O'Z1>5,$'4>NP$GK"H@):#8C2>>KA;N`@"Y_!O!MWZP5
M")`!C/4OA!`(T(!!-)!3;!1$Q'RV"$XK0(?2FYX.?#^HWD\O3X8WWJ8@M_Q"
M='&!KEIAE[DNL$57ZF:,O#33"0'I`4+/&4)00`-,!WH%?M[W"+A]((Z%O4#F
M_/R*^'.AV,=^S3&RBP=D'_L1L,`4DC\174Q4]@N!!A$B`.8+=*`#&T@J00&!
M;H:\-@*'3P@@(J"!^D<&&H3`#`R1#(1`?@^!#@6X=3+5#H2@#-9$"((@"($0
M@1%("'$W$0P8@1.(<KJ0#.C7$.,D@!S135/P`1J0`1B0`1Q`!("@:!/13;K@
M@I2E"X3@?\8T%-&$:U5W@SS8@S[X@T`8A/]".(1$6(1&>(1(F(1*N(1B40_"
MT`ON@(3AD`Q4F`S2@%;X%0Y1.!#LH`X&T0_KH`\.40_HP`\*44O^\`U;&!):
MV`_A((8#\0WQ8!#AP`>!0`B,D`U&B`]E\`%&952+(`\&X0^E$`GY4`:),!#]
M<`J1`(=Q2`?1X!"J4`7PD!#^$`J3,`])<`@CP0F9\`U08`T#@0\O,`D%X0^D
M@`I9@`>^L`MF2(3XD`:.(!#U(`I9<`W_X`_/D`QZ.`YGP`784`:&\`W*,(?K
MH`[Y``[K8(7\\`V0F`_0((BYN`[&Z(7W``VJP`31D`Q>^`_WT`Q6J`^^R`70
M0`:.X`]3R`QS.!#_^?`-Z)`,V/"*\Y`,RI`.`M$/T&"%M)B/V6"&:O@-3S`)
MS8`-^D"*IE@/SZ`,ZH`/I%`,=P`(TN"*11B+E2`0_J`*62`-_2`*PD0'OH`,
M,5`"DD`&1D`'48`([1`*B_`,5"!,4D`)SL@+ID`'W"`0\_`'DW`/<S`&\>`-
M5U`*+-`%5!`&V7`/?2!,4[`+QQ"2DP`*T>`-:#`%4[`(Z_@/WJ`$7F`%6>"*
MX=`&4F`%7A`-^<"15B`%T5"+PI0%8ND&EO`-,I`%5C`%DT`/I5@/?R!,=H`-
MP#`(DZ!+OK"'95`$IA<%=_`.WE`$>D`(;9`%SX`&8:`-97`"RA`*4B`-_WZ`
M""`Y!L_P!EO@C*7'"P-Q#W^`".$0F=G0"85P"BOP",$@!9/@#5G@"\$PE-!P
M!F+`#?.0#Y]0!+I@#+T@C5:I`HCP#'N0!=L@!U?`#,VP!V&P#&80!KV@"]$0
M#FGP!=%YA3/@"-\``X@`#7]P!=10BJJ`F(-`!8B`#L'`"(2P"VLXA'QX!8!P
M!B`0!O;X"7YH5,FY!XAPB(;P#]]0!;QPF<B`!)&8"E?P#$_@`5^PAA=)![I`
M!T70"V6@":JP!-Q@#V@P">SP!W2`!BJ0!>B@GW"H"BM@!'H@#:]HE5%0D[#Y
M"RZ`"0+A#6RP"WM`!%V@!^]0#W-`!%F@".[@#__9"8K5\`_A4`6_4(J<X`%&
MM0(+V@^V5I6P*(OYL`YQ<`79X`^>D)RVE@[SH)^'F(A%N@L"N@2BJ`H'B@91
M4`21.!#>4'J+H`9YT`+O,(GP<`]H\`CC20>,X`=>$**(`(?]8`Q[X`1JRJ94
MT`U6F06]X`*;$*-L$`WM<`IT0`17\`[S4`J3J@7J$*104)/AT`1'.@ERD)&V
MUHU*2)$"$0YF<`?RH`HC(`W^,`QU@`Y\L)^(2*15(*:82:;_8*;/X*!I``95
M.0]P8`*3\`E$@`*]2HEVJ@AS@`7QP`YI`*(BFJK8D`_>L`2F&*,Q<`G^\`E9
MD`UE``;ZT`_@*@W0<%;_LR`"UZ"&NID%V!"D,C"+9CH-I3@*17`-]Z"2P(F$
M^/`&EF"1JA`%O%`/;T`"1C4)^X"LC7"KX8`&O/`)F$D%-8F1O_J41+"FN;B;
MTN`-*D"O65"G=#`)JJ`"1N4!5X`-R)H(9J@*?QBN;)H"14`$13`)_.`-?UBS
M\["C1E4([,"S1(`(\;`&E1`.,C"S1+`(]$`&F3`/98"P10":3*B&BM@,>N@/
MPJ`+TF"3PB`-5NN-T.`.X9`-\RB(\R`-]2"'__"U7`@-^G`/R1"%\^`,_.`/
MT&"/WZ!+V.`,\3`/6AN'NL">!.$-1Q`-6BN/NJ2'WIBUNT"+62L-8N@-W%`/
M*\V02RCZ#\00A4ZH"XK+A$SA#13KN73AM_TJNJ9[NJB;NJJ[NJS;NJ[[NK`V
M&[NR.[NT6[NV>[NXF[NZN[N\V[N^^[O`&[S".[S$6[S&>[S(F[S*N[S,V[S.
M^[S0&[W2.[W4-%N]UGN]V)N]VKN]W-N]WON]X!N^XCN^Y%N^YGN^Z)N^ZKN^
3[-N^[ON^\!N_\CN_]%M``0$`.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
